Applied Therapeutics (APLT)

• Market cap: $58.1M
• 1 day: -4.35%
• 5 days: 1.98%
• 1 month: -15.69%
• 3 months: -56.55%
• 6 months: -89.78%
• Year to date: -44.37%
• 1 year: -91.82%
• 5 years: -98.20%
• 10 years: -94.68%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Employees: 37

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

62% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 26

47% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $969K

0.7% more ownership

Funds ownership: 98.19% [Q3] → 98.89% (+0.7%) [Q4]

6% less funds holding

Funds holding: 125 [Q3] → 118 (-7) [Q4]

13% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 45

50% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]

90% less capital invested

Capital invested by funds: $961M [Q3] → $98.5M (-$863M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $1.50 200% upside
• Avg. target: $1.50 200% upside
• High target: $1.50 200% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

RBC Capital Brian Abrahams 15% 1-year accuracy 11 / 71 met price target

200% upside $1.50

Sector Perform Maintained

20 Dec 2024